文献速递肝病

原发性胆汁性胆管炎国际全基因组荟萃分析:新风险位点与候选药物

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.
PubMed 文献 · J Hepatol · 2021-05-23

该研究纳入10,516例PBC病例和20,772例对照,来自5个欧洲和2个东亚队列,进行迄今最大的全基因组荟萃分析。研究识别56个全基因组显著位点(20个新位点),条件分析另发现第57个新位点。通路分析强调模式识别受体、TNF、JAK-STAT信号及Th1/Th17分化的重要性,药物效力筛选预测了若干可能治疗PBC的药物。

要点

  • 识别56个全基因组显著位点,其中20个为新位点,条件分析另发现1个新位点。
  • 新位点候选基因包括FCRL3、INAVA、PRDM1、IRF7、CCR6、CD226和IL12RB1,均参与免疫。
  • 药物效力筛选预测若干药物可能对PBC有治疗作用,部分已用于其他自身免疫病。

核心结论

  • 研究识别了PBC的额外风险位点,提供了可试验药物的优先级列表,并强调遗传与基因组方法在复杂疾病药物发现中的价值。

研究设计与样本

  • 研究为全基因组荟萃分析,合并新和现有基因型数据,纳入10,516例病例和20,772例对照,来自5个欧洲和2个东亚队列。

主要发现

  • 识别56个全基因组显著位点(20个新位点),包括46个在欧洲队列、13个在亚洲队列、41个在合并队列中显著。
  • 在欧洲队列的条件分析中识别第57个全基因组显著位点(也为新位点)。
  • 新位点候选基因包括FCRL3、INAVA、PRDM1、IRF7、CCR6、CD226和IL12RB1,各在免疫中起关键作用。
  • 通路分析重申模式识别受体和TNF信号、JAK-STAT信号以及Th1和Th17细胞分化在PBC发病中的可能重要性。
  • 药物效力筛选识别若干预测对PBC有治疗作用的药物,部分已确立用于其他自身免疫病。

临床怎么用

  • 研究结果为PBC临床试验提供了候选药物的优先级层级,可指导未来药物试验选择。
  • 遗传与基因组方法可用于复杂疾病的药物发现,支持将新风险位点候选基因用于计算机药物效力筛选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDS & AIMS: Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruction of the small intrahepatic bile ducts eventually leads to cirrhosis. Many patients have inadequate response to licensed medications, motivating the search for novel therapies. Previous genome-wide association studies (GWAS) and meta-analyses (GWMA) of PBC have identified numerous risk loci for this condition, providing insight into its aetiology. We undertook the largest GWMA of PBC to date, aiming to identify additional risk loci and prioritise candidate genes for in silico drug efficacy screening. METHODS: We combined new and existing genotype data for 10,516 cases and 20,772 controls from 5 European and 2 East Asian cohorts. RESULTS: We identified 56 genome-wide significant loci (20 novel) including 46 in European, 13 in Asian, and 41 in combined cohorts; and a 57th genome-wide significant locus (also novel) in conditional analysis of the European cohorts. Candidate genes at newly identified loci include FCRL3, INAVA, PRDM1, IRF7, CCR6, CD226, and IL12RB1, which each play key roles in immunity. Pathway analysis reiterated the likely importance of pattern recognition receptor and TNF signalling, JAK-STAT signalling, and differentiation of T helper (TH)1 and TH17 cells in the pathogenesis of this disease. Drug efficacy screening identified several medications predicted to be therapeutic in PBC, some of which are well-established in the treatment of other autoimmune disorders. CONCLUSIONS: This study has identified additional risk loci for PBC, provided a hierarchy of agents that could be trialled in this condition, and emphasised the value of genetic and genomic approaches to drug discovery in complex disorders. LAY SUMMARY: Primary biliary cholangitis (PBC) is a chronic liver disease that eventually leads to cirrhosis. In this study, we analysed genetic information from 10,516 people with PBC and 20,772 healthy individuals recruited in Canada, China, Italy, Japan, the UK, or the USA. We identified several genetic regions associated with PBC. Each of these regions contains several genes. For each region, we used diverse sources of evidence to help us choose the gene most likely to be involved in causing PBC. We used these 'candidate genes' to help us identify medications that are currently used for treatment of other conditions, which might also be useful for treatment of PBC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Cordell HJ, Fryett JJ, Ueno K, et al. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. J Hepatol. 2021. PMID: 34033851. doi:10.1016/j.jhep.2021.04.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。